阿尔茨海默病疾病修饰药物研发述评
作者:
作者单位:

作者简介:

通讯作者:

基金项目:

首都卫生发展科研专项项目(首发 2020-2-2191)


Review on research of disease-modifying pharmacological therapy for Alzheimer disease
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    阿尔茨海默病(AD)是最常见的神经系统变性疾病之一,疾病负担沉重。目前 AD 发病机 制未明,缺乏能够逆转或延缓疾病进展的疾病修饰药物。现阐述基于 AD 主要发病机制学说的疾病修 饰药物研究,包括以Aβ、tau或其他生物标志物为靶点及老药新用的药物试验。其中,绝大部分药物试 验终止于研发或临床试验进程的某一阶段,也有一些正在进行。AD发病机制研究与疾病修饰药物研发 之间是互相促进和验证的关系,基础研究的突破有可能为药物研发带来新的希望,而某个方向药物试验 的成败又是对其理论基础的检验。从探索 AD 致病机制,到研发疾病修饰药物,至广泛临床应用的道路 仍然漫长。

    Abstract:

    Alzheimer disease (AD) is one of the most common neurodegenerative disease with a heavy disease burden. At present, the pathogenesis of AD is unknown. Therefore, there is a lack of disease modifying medicines that can reverse or delay the progress of AD. This paper describes the research on disease modifying pharmacological therapy based on the theory of main pathogenesis of AD. It includes the research using Aβ, tau or other biomarkers as targets and new clinical trials of old medicines. Among them, most trials terminated at a certain stage of the drug research and development process or clinical trial process, and some are still ongoing. The relationship between AD pathogenesis research and disease modifying therapy is mutual promotion and verification. The breakthrough of basic research may bring new hope to drug research and development. At the same time, the success or failure of clinical trial in a certain direction is a test of its theoretical basis. There is still a long way to go from the research on the pathogenesis of AD to the development of disease modifying medicines, and then to their widely clinical use.

    参考文献
    相似文献
    引证文献
引用本文

吕继辉.阿尔茨海默病疾病修饰药物研发述评[J].神经疾病与精神卫生,2022,22(11):
DOI :10.3969/j. issn.1009-6574.2022.11.001.

复制
文章指标
  • 点击次数:
  • 下载次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2022-12-22